Results 101 to 110 of about 6,071 (199)

Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. [PDF]

Vaccines (Basel)
Kura K, Lang JC, Wang D, Choi Y, Goveia MG, Sinha A, Chen YH, Elbasha EH.   +7 more
europepmc   +1 more source

Meta-analysis of the efficacy of palivizumab versus nirsevimab at preventing medically attended respiratory syncytial virus infections in non-hospitalized preterm infants. [PDF]

Hum Vaccin Immunother
Fullarton J, Paes B, Waghorne N, Keary I, Rodgers-Gray B, Carbonell-Estrany X.   +5 more
europepmc   +1 more source

Comparative Analysis of Reported Adverse Events with Nirsevimab and Palivizumab: A FAERS Observational Study. [PDF]

Kans J Med
Touffaha I, Ablah E, Okut H, Homan G.
europepmc   +1 more source

Enflonsia (clesrovimab) and the future of RSV lower respiratory tract disease prevention in neonates. [PDF]

Ann Med Surg (Lond)
Chandani HK, Hujjat SFZ, Chandani DK, Khan MS, Mahmoud A.   +4 more
europepmc   +1 more source

Clinical and economic evaluation of risk factor guided respiratory syncytial virus prophylaxis in Colombian preterm infants. [PDF]

Cost Eff Resour Alloc
Rodriguez-Martinez CE, Ordonez J, Carbonell-Estrany X, Fullarton J, Keary I, Rodgers-Gray B, D'Apremont I, Noyola DE, Ribeiro PA, Stein RT, Vain N, Tarride JE, Paes B.   +12 more
europepmc   +1 more source

Reliability of RSV Antigen Diagnostic Tests in the Presence of Nirsevimab. [PDF]

Pediatr Infect Dis J
Sincero SR, Mahool KA, Schaefer E, Caceres CS, Caceres CS, Kelly EJ, Wilkins D, Tuffy KM.   +7 more
europepmc   +1 more source

Factors Affecting Maternal Respiratory Syncytial Virus Vaccination and the Impact on Infant Hospitalization During the 2023-2024 Season in Dallas, Texas. [PDF]

Public Health Rep
Bailey NA, Most ZM.
europepmc   +1 more source

Palivizumab for preterm infants. Is it worth it?

Respiratory syncytial virus infection is an important cause of morbidity. Although palivizumab prophylaxis is widely used, it is uncertain whether the cost is justified.
Harkensee C, Embleton ND, Mckean MC
core  

Bivalent RSV prefusion F vaccination elicits effective neutralization of contemporary and monoclonal antibody-resistant RSV strains. [PDF]

NPJ Vaccines
Chen W, Martinez LT, Falcao L, Li Z, McKeen AP, Kurhade C, Boigard H, Roopchand V, Richardson I, Dasgupta T, Llamera KE, Colatat J, Brock LG, Anderson AS, Swanson KA.   +14 more
europepmc   +1 more source

The Effectiveness of Respiratory Syncytial Virus Prophylaxis Programme using Palivizumab in Preterm Infants: <i>A single institute retrospective study</i>. [PDF]

Sultan Qaboos Univ Med J
Al Mandhari H, Al Kendi S, Al-Balushi N, Bintaqi A, Al Saadi A, Abdellatif M.   +5 more
europepmc   +1 more source